NEUMORA THERAPEUTICS, INC. (NMRA) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $19.00K; Additional Paid in Capital, Common StockUSD $1.33B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD $-1.28B.
- 2026-03-31: Common Stock, Value, IssuedUSD $18.00K; Additional Paid in Capital, Common StockUSD $1.31B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD $-1.24B.
- 2025-12-31: Common Stock, Value, IssuedUSD $17.00K; Additional Paid in Capital, Common StockUSD $1.29B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD $-1.18B.
- 2025-09-30: Common Stock, Value, IssuedUSD $16.00K; Additional Paid in Capital, Common StockUSD $1.26B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $9.00K; Retained Earnings (Accumulated Deficit)USD $-1.12B.
NEUMORA THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | Preferred Stock, Value, Issued USD | Preferred Stock, Value, Outstanding USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $19.00K | $1.33B | (m) | $-1.28B | $44.52M | 3 month · $7.18M | (m) | (m) |
| 2026-03-31 | $18.00K | $1.31B | (m) | $-1.24B | $70.68M | 3 month · $7.41M | (m) | (m) |
| 2025-12-31 | $17.00K | $1.29B | (m) | $-1.18B | $103.87M | 12 month · $29.88M | (m) | (m) |
| 2025-09-30 | $16.00K | $1.26B | $9.00K | $-1.12B | $132.16M | 3 month · $5.98M | (m) | (m) |
| 2025-06-30 | $16.00K | $1.25B | $-15.00K | $-1.07B | $182.88M | 3 month · $7.17M | (m) | (m) |
| 2025-03-31 | $16.00K | $1.24B | $-3.00K | $-1.02B | $228.36M | 3 month · $9.32M | (m) | (m) |
| 2024-12-31 | $16.00K | $1.23B | $62.00K | $-947.22M | $287.06M | 12 month · $39.99M | (m) | (m) |
| 2024-09-30 | $16.00K | $1.21B | $105.00K | $-888.40M | $320.74M | 3 month · $9.95M | (m) | (m) |
| 2024-06-30 | $16.00K | $1.20B | $-187.00K | $-815.86M | $381.26M | 3 month · $12.77M | (m) | (m) |
| 2024-03-31 | $16.00K | $1.18B | $-148.00K | $-757.15M | $424.54M | 3 month · $7.37M | (m) | (m) |
| 2023-12-31 | $16.00K | $1.17B | $-76.00K | $-703.43M | $469.08M | 12 month · $17.24M | $0.00 | $0.00 |
| 2023-09-30 | $15.00K | $1.11B | $-311.00K | $-594.70M | $512.69M | 3 month · $6.45M | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | $-513.54M | 3 month · $2.54M | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | $-477.92M | 3 month · $2.19M | (m) | (m) |
| 2022-12-31 | $3.00K | $21.43M | $-774.00K | $-467.51M | $-446.85M | 12 month · $8.30M | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | $-422.00M | 3 month · $2.10M | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | $-394.71M | 3 month · $1.75M | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | $-366.02M | 3 month · $1.65M | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | $-325.22M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |